Report Content
- Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
- Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
- Executive Summary
- Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter''s Five Force Analysis
- Peptide and Anticoagulant Drugs Market, By Type
5.1 Introduction
5.2 Hormonal
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Antibiotic
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Ace Inhibitors
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Antifungal
5.5.1 Market Overview
5.5.2 Market Size and Forecast
5.6 Other Peptide Drugs
5.6.1 Market Overview
5.6.2 Market Size and Forecast
- Peptide and Anticoagulant Drugs Market, By Application
6.1 Introduction
6.2 Diabetes
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Infectious Diseases
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Cancer
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Osteoporosis
6.5.1 Market Overview
6.5.2 Market Size and Forecast
6.6 Cardiology
6.6.1 Market Overview
6.6.2 Market Size and Forecast
6.7 Gynecology
6.7.1 Market Overview
6.7.2 Market Size and Forecast
6.8 Other Applications
6.8.1 Market Overview
6.8.2 Market Size and Forecast
- Peptide and Anticoagulant Drugs Market, By Low Molecular Weight Heparin Type
7.1 Introduction
7.2 Enoxaparin Sodium
7.2.1 Market Overview
7.2.2 Market Size and Forecast
7.3 Heparin Sodium
7.3.1 Market Overview
7.3.2 Market Size and Forecast
7.4 Fondaparinux
7.4.1 Market Overview
7.4.2 Market Size and Forecast
7.5 Dalteparin Sodium
7.5.1 Market Overview
7.5.2 Market Size and Forecast
- Peptide and Anticoagulant Drugs Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 North America Peptide and Anticoagulant Drugs, By Type
8.2.2 North America Peptide and Anticoagulant Drugs, By Application
8.2.3 North America Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type
8.3 Europe
8.3.1 Europe Peptide and Anticoagulant Drugs, By Type
8.3.2 Europe Peptide and Anticoagulant Drugs, By Application
8.3.3 Europe Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type
8.4 Asia-Pacific
8.4.1 Asia-Pacific Peptide and Anticoagulant Drugs, By Type
8.4.2 Asia-Pacific Peptide and Anticoagulant Drugs, By Application
8.4.3 Asia-Pacific Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type
8.5 Rest of the World
8.5.1 Rest of the World Peptide and Anticoagulant Drugs, By Type
8.5.2 Rest of the World Peptide and Anticoagulant Drugs, By Application
8.5.3 Rest of the World Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type
- Competitive Insights
9.1 Key Insights
9.2 Company Market Share Analysis
9.3 Strategic Outlook
9.3.1 Mergers & Acquisitions
9.3.2 New Product Development
9.3.3 Portfolio/Production Capacity Expansions
9.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
9.3.5 Others
- Company Profiles
- Abbott Laboratories
- Sanofi S.A.
- Eli Lilly and Company
- Cipla Limited
- Biocon Limited
- Intas Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd
- Cadila Pharmaceuticals
- Lupin Limited
- Emcure Pharmaceuticals Ltd
- Novartis International AG
- Reddy’s Laboratories Limited
- Alkem Laboratories Limited